Autolus Therapeutics plc
AUTL · NASDAQ
Bulios Fair Price
$1.28
33.3% downside
Trenutna cena
$1.92
Po podatkih Bulios Fair Price je delnica AUTL trenutno precenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
O podjetju
Autolus Therapeutics plc (AUTL) is a biotechnology company focused on developing immunotherapeutic drugs for cancer treatment. Utilizing advanced technologies in the field of gene engineering and cell therapy, Autolus Therapeutics aims to develop innovative therapies that selectively target cancer cells and minimize the side effects of traditional treatment methods. The company focuses on developing personalized treatment approaches that take into account individual genetic characteristics of patients. With its commitment to research and development, Autolus Therapeutics offers hope for new, effective therapeutic options in the fight against cancer. Autolus Therapeutics plc (AUTL) shares could be suitable for investors looking for investments in biotechnology with an emphasis on innovative cancer treatment.
V vašem jeziku še ni na voljo, zato je besedilo v angleščini.
Sector
Healthcare
Industry
Biotechnology
CEO
Christian Martin Itin
Employees
752
Headquarters
London
Prihajajoči dogodki
Earnings
Upcoming earnings report